Rituximab <i>versus</i> intravenous cyclophosphamide for anti-neutrophil cytoplasmic antibody-associated vasculitis with severe renal impairment: A multicentre REVEAL cohort study
RTX and IVCY demonstrated comparable efficacy in preventing mortality and ESKD in this high-risk population. RTX is a viable option for patients with AAV and severe renal impairment.
Authors
- Shuji Sumitomo (ORCID: https://orcid.org/0000-0003-4980-2664)
- Yohei Fujiki
- Mikihito Shoji
- Hirofumi Miyake (ORCID: https://orcid.org/0000-0001-5655-6356)
- Mochammad Hatta (ORCID: https://orcid.org/0000-0002-8456-4203)
- Kwang-Wook Jo (ORCID: https://orcid.org/0000-0001-7993-3409)
- Hideki Oka (ORCID: https://orcid.org/0000-0002-9810-7644)
- Motomu Hashimoto (ORCID: https://orcid.org/0000-0002-9241-060X)
- Tomoki Taniguchi (ORCID: https://orcid.org/0000-0003-0244-6826)
- Ryosuke Hiwa (ORCID: https://orcid.org/0000-0001-6968-5712)
- Mayu Shiomi (ORCID: https://orcid.org/0009-0008-8992-1805)
- Ayana Okazaki
- Takuya Kotani (ORCID: https://orcid.org/0000-0003-2190-0780)
- Wataru Yamamoto (ORCID: https://orcid.org/0000-0002-0810-4221)
- Ryu Watanabe (ORCID: https://orcid.org/0000-0002-1089-5296)
- Shogo Matsuda (ORCID: https://orcid.org/0000-0002-8436-2046)
- Atsushi Manabe (ORCID: https://orcid.org/0000-0002-3264-8261)
- Yuichi Masuda
Institutions
- Kyoto University (JP)
- Tenri Hospital (JP)
- Kurashiki Central Hospital (JP)
- Yodogawa Christian Hospital (JP)
- Kobe City Medical Center General Hospital (JP)
- Osaka Metropolitan University (JP)
- Osaka University of Pharmaceutical Sciences (JP)
Publication Details
- Journal
- Modern Rheumatology
- Published
- 2025-12-11
- DOI
- https://doi.org/10.1093/mr/roaf124
- Primary Topic
- Vasculitis and related conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00